Arabic Arabic English English French French German German
dark

Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

Providence Therapeutics announced additional results from its Phase 1 study, PRO-CL-001, of PTX-COVID19-B. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Next Post

Children of cancer patients are too often excluded from the disease journey, research shows

Related Posts
Total
0
Share